Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

neuron

Neurology comes to the fore

September 7, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Alzheimer's disease, multiple sclerosis, neurology

Neurology is an area where pharma has struggled to deliver in recent years.Yet the high unmet need for drugs to …
Feature
revlimid_celgene

Celgene threatens to scale back UK clinical trial investment after CDF snub

September 4, 2015 Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
News

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015 Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
News
NHS sign

Companies braced for new round of cancer cuts

September 4, 2015 Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NHS England, cuts

Several treatments that extend the lives of people with cancer are expected to be removed from the Cancer Drugs Fund …
News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015 Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …
News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015 Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus
News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015 Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
News

NICE pushes biosimilars in rheumatoid arthritis guidance

September 3, 2015 Sales and Marketing

NICE has published final draft guidance confirming its recommended treatment options for rheumatoid arthritis.  For the first time copycat, or …
News
zarxio

Sandoz launches first US biosimilar

September 3, 2015 Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
News
dun___bradstreet_4efa511357b57

Shire appoints Sara Mathew to board of directors

September 2, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire

Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Appointment
Novartis image

Two Novartis drugs get first in class EU approvals

September 2, 2015 Research and Development, Sales and Marketing Novartis

The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
News
scales

Standardising the pharma benefit-risk assessment process

September 1, 2015 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, FDA, benefit-risk analysis, pharmacoepidemiology, pharmacovigilance

Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …
Feature
Alexion sign

Alexion scores double EU approval

September 1, 2015 Manufacturing and Production, Sales and Marketing Alexion, EC, European Commission, Kanuma, Strensiq, asfotase alfa, sebelipase alfa, ultra rare disease, ultra-rare disease

Two treatments developed by ultra-rare disease specialists Alexion Pharmaceuticals are now approved for use in Europe. The European Commission approved …
News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015 Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …
News

Novo Nordisk to buy two pharma research companies

August 27, 2015 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, mergers and acquisitions

Novo Nordisk is to acquire two privately-held biopharmaceutical research companies specialising in diabetes, for undisclosed sums. Calibrium and MB2, formed …
News
The Gateway to Local Adoption Series

Latest content

Cori Clinical raises US$4m to expand AI platform for clinical trial design

October 14, 2026

Ofichem acquires US drug substance CDMO Kinentia

October 14, 2026

Jager-van Dijk is new Arletta Pharma Solutions CEO 

October 13, 2026

Tridem begins phase Ib trial of Parkinson’s disease vaccine

October 13, 2026

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol

October 13, 2026